Acute myocardial infarction
Acute myocardial infarction is a common disease with serious consequences in mortality, morbidity, and cost to the society. Coronary atherosclerosis plays a pivotal part as the underlying substrate in many patients. In addition, a new definition of myocardial infarction has recently been introduced that has major implications from the epidemiological, societal, and patient points of view. The advent of coronary-care units and the results of randomised clinical trials on reperfusion therapy, lytic or percutaneous coronary intervention, and chronic medical treatment with various pharmacological agents have substantially changed the therapeutic approach, decreased in-hospital mortality, and improved the long-term outlook in survivors of the acute phase. New treatments will continue to emerge, but the greatest challenge will be to effectively implement preventive actions in all high-risk individuals and to expand delivery of acute treatment in a timely fashion for all eligible patients.
| Errataetall: |
CommentIn: Lancet. 2003 Jun 14;361(9374):2087. - PMID 12814749 |
|---|---|
| Medienart: |
Artikel |
| Erscheinungsjahr: |
2003 |
|---|---|
| Erschienen: |
2003 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:361 |
|---|---|
| Enthalten in: |
Lancet (London, England) - 361(2003), 9360 vom: 08. März, Seite 847-58 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Boersma, Eric [VerfasserIn] |
|---|
| Themen: |
EC 3.4.- |
|---|
| Anmerkungen: |
Date Completed 04.04.2003 Date Revised 10.03.2022 published: Print CommentIn: Lancet. 2003 Jun 14;361(9374):2087. - PMID 12814749 Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM124160026 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM124160026 | ||
| 003 | DE-627 | ||
| 005 | 20231222202934.0 | ||
| 007 | tu | ||
| 008 | 231222s2003 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0414.xml |
| 035 | |a (DE-627)NLM124160026 | ||
| 035 | |a (NLM)12642064 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Boersma, Eric |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Acute myocardial infarction |
| 264 | 1 | |c 2003 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 04.04.2003 | ||
| 500 | |a Date Revised 10.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Lancet. 2003 Jun 14;361(9374):2087. - PMID 12814749 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Acute myocardial infarction is a common disease with serious consequences in mortality, morbidity, and cost to the society. Coronary atherosclerosis plays a pivotal part as the underlying substrate in many patients. In addition, a new definition of myocardial infarction has recently been introduced that has major implications from the epidemiological, societal, and patient points of view. The advent of coronary-care units and the results of randomised clinical trials on reperfusion therapy, lytic or percutaneous coronary intervention, and chronic medical treatment with various pharmacological agents have substantially changed the therapeutic approach, decreased in-hospital mortality, and improved the long-term outlook in survivors of the acute phase. New treatments will continue to emerge, but the greatest challenge will be to effectively implement preventive actions in all high-risk individuals and to expand delivery of acute treatment in a timely fashion for all eligible patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 650 | 7 | |a Streptokinase |2 NLM | |
| 650 | 7 | |a EC 3.4.- |2 NLM | |
| 650 | 7 | |a Tissue Plasminogen Activator |2 NLM | |
| 650 | 7 | |a EC 3.4.21.68 |2 NLM | |
| 700 | 1 | |a Mercado, Nestor |e verfasserin |4 aut | |
| 700 | 1 | |a Poldermans, Don |e verfasserin |4 aut | |
| 700 | 1 | |a Gardien, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Vos, Jeroen |e verfasserin |4 aut | |
| 700 | 1 | |a Simoons, Maarten L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lancet (London, England) |d 1945 |g 361(2003), 9360 vom: 08. März, Seite 847-58 |w (DE-627)NLM000473936 |x 1474-547X |7 nnns |
| 773 | 1 | 8 | |g volume:361 |g year:2003 |g number:9360 |g day:08 |g month:03 |g pages:847-58 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 361 |j 2003 |e 9360 |b 08 |c 03 |h 847-58 | ||